CY1105263T1 - Χρηση συμπολυμepους (copolymer) 1 και συναφων πεπτιδιων και πολυπεπτιδιων και t-λεμφοκυτταρων που εχουν υποβληθει σε αγωγη με αυτα για νευροπροστατευτικη θepαπεια - Google Patents
Χρηση συμπολυμepους (copolymer) 1 και συναφων πεπτιδιων και πολυπεπτιδιων και t-λεμφοκυτταρων που εχουν υποβληθει σε αγωγη με αυτα για νευροπροστατευτικη θepαπειαInfo
- Publication number
- CY1105263T1 CY1105263T1 CY20061100219T CY061100219T CY1105263T1 CY 1105263 T1 CY1105263 T1 CY 1105263T1 CY 20061100219 T CY20061100219 T CY 20061100219T CY 061100219 T CY061100219 T CY 061100219T CY 1105263 T1 CY1105263 T1 CY 1105263T1
- Authority
- CY
- Cyprus
- Prior art keywords
- cop
- nervous system
- polypeptide
- related peptide
- polypeptides
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 10
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 6
- 229920001184 polypeptide Polymers 0.000 title abstract 5
- 210000001744 T-lymphocyte Anatomy 0.000 title abstract 3
- 229920001577 copolymer Polymers 0.000 title 1
- 238000011859 neuroprotective therapy Methods 0.000 title 1
- 210000003169 central nervous system Anatomy 0.000 abstract 2
- 210000005036 nerve Anatomy 0.000 abstract 2
- 210000000653 nervous system Anatomy 0.000 abstract 2
- 230000004770 neurodegeneration Effects 0.000 abstract 2
- 210000001428 peripheral nervous system Anatomy 0.000 abstract 2
- 230000008929 regeneration Effects 0.000 abstract 2
- 238000011069 regeneration method Methods 0.000 abstract 2
- 208000027418 Wounds and injury Diseases 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 230000006378 damage Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000014674 injury Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/46432—Nervous system antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/47—Brain; Nervous system
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Cell Biology (AREA)
- Diabetes (AREA)
- Psychiatry (AREA)
- Hematology (AREA)
- Zoology (AREA)
- Addiction (AREA)
- Obesity (AREA)
- Ophthalmology & Optometry (AREA)
- Marine Sciences & Fisheries (AREA)
- Psychology (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Endocrinology (AREA)
- Nutrition Science (AREA)
- Emergency Medicine (AREA)
Abstract
Παρέχονται μέθοδοι για θεραπευτική αγωγή κάκωσης ή νόσου του κεντρικού ή περιφερικού νευρικού συστήματος. Σε μία υλοποίηση, η θεραπευτική αγωγή πραγματοποιείται χορηγώντας ενεργοποιημένα Τ-λεμφοκύτταρα που αναγνωρίζουν αντιγόνο Cop 1 ή πεπτίδιο ή πολυπεπτίδιο συναφές του Cop 1 για την προαγωγή αναγέννησης νεύρων ή αποτροπή ή αναστολή νευρωνικού εκφυλισμού στο νευρικό σύστημα. Σε άλλη υλοποίηση, η θεραπευτική αγωγή ενέχει χορήγηση Cop 1 ή πεπτιδίου ή πολυπεπτιδίου συναφούς του Cop 1 για προαγωγή αναγέννησης νεύρων ή για αποτροπή ή αναστολή νευρωνικού εκφυλισμού στο νευρικό σύστημα, είτε στο κεντρικό νευρικό σύστημα ή στο περιφερικό νευρικό σύστημα. Τα ενεργοποιημένα Τ-λεμφοκύτταρα, που έχουν ενεργοποιηθεί με την παρουσία Cop 1 ή πεπτιδίου ή πολυπεπτιδίου συναφούς του Cop 1, μπορούν να χορηγηθούν από μόνα τους ή σε συνδυασμό με Cop 1 ή με πεπτίδιο ή πολυπεπτίδιο συναφές του Cop 1.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US20979900P | 2000-06-07 | 2000-06-07 | |
US62021600A | 2000-07-20 | 2000-07-20 | |
PCT/US2001/002118 WO2001093893A2 (en) | 2000-06-07 | 2001-01-22 | The use of copolymer 1 and related peptides and polypeptides and t cells treated therewith for neuroprotective therapy |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1105263T1 true CY1105263T1 (el) | 2010-03-03 |
Family
ID=26904524
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20061100219T CY1105263T1 (el) | 2000-06-07 | 2006-02-16 | Χρηση συμπολυμepους (copolymer) 1 και συναφων πεπτιδιων και πολυπεπτιδιων και t-λεμφοκυτταρων που εχουν υποβληθει σε αγωγη με αυτα για νευροπροστατευτικη θepαπεια |
Country Status (17)
Country | Link |
---|---|
US (1) | US20020037848A1 (el) |
EP (1) | EP1294390B1 (el) |
JP (1) | JP4328090B2 (el) |
KR (1) | KR20030007397A (el) |
CN (1) | CN100438906C (el) |
AT (1) | ATE314860T1 (el) |
AU (1) | AU783031B2 (el) |
CA (1) | CA2398277C (el) |
CY (1) | CY1105263T1 (el) |
DE (1) | DE60116467T2 (el) |
DK (1) | DK1294390T3 (el) |
ES (1) | ES2256200T3 (el) |
HK (1) | HK1058892A1 (el) |
IL (2) | IL150801A0 (el) |
MX (1) | MXPA02007109A (el) |
NZ (1) | NZ520282A (el) |
WO (1) | WO2001093893A2 (el) |
Families Citing this family (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2527760T3 (es) | 1998-07-23 | 2015-01-29 | Yeda Research And Development Co., Ltd. | Tratamiento de enfermedad de Crohn con copolímero 1 y polipéptidos |
IL141021A0 (en) | 1998-07-23 | 2002-02-10 | Yeda Res & Dev | Treatment of autoimmune conditions with copolymer 1 and related copolymers |
US6800287B2 (en) | 1998-09-25 | 2004-10-05 | Yeda Research And Development Co., Ltd. | Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use |
ZA200206457B (en) | 2000-02-18 | 2003-08-13 | Yeda Res & Dev | Oral, nasal and pulmonary dosage formulations of copolymer 1. |
US20020077278A1 (en) | 2000-06-05 | 2002-06-20 | Yong V. Wee | Use of glatiramer acetate (copolymer 1) in the treatment of central nervous system disorders |
WO2001093828A1 (en) * | 2000-06-05 | 2001-12-13 | Teva Pharmaceuticals Industries, Ltd. | The use of glatiramer acetate (copolymer 1) in the treatment of central nervous system disorders |
WO2002076503A1 (en) * | 2000-06-20 | 2002-10-03 | Mayo Foundation For Medical Education And Research | Treatment of central nervous system diseases by antibodies against glatiramer acetate |
DE60237170D1 (de) * | 2001-12-04 | 2010-09-09 | Teva Pharma | Verfahren zur messung der wirkstärke von glatirameracetat |
ES2322566T3 (es) * | 2001-12-06 | 2009-06-23 | Yeda Research And Development Co., Ltd. | Vacuna y uso de la misma para el tratamiento de la esclerosis lateral amiotrofica. |
CA2512735C (en) * | 2003-01-07 | 2016-03-08 | Yeda Research And Development Co. Ltd. | Eye-drop vaccine containing copolymer 1 for therapeutic immunization |
JP4632953B2 (ja) * | 2003-09-29 | 2011-02-16 | 中外製薬株式会社 | Nk細胞に発現するタンパク質 |
EP1677737A4 (en) * | 2003-10-03 | 2008-04-16 | Bayhill Therapeutics Inc | TREATMENT OF DEMYELINIZING AUTOIMMUNE DISEASE WITH MODIFIED ORDERED PEPTIDES |
EP2301569B1 (en) | 2003-11-12 | 2018-05-02 | Yeda Research and Development Co. Ltd. | Vaccine and method for treatment of neurodegenerative diseases |
EP1701730B1 (en) * | 2003-12-09 | 2013-08-21 | Yeda Research And Development Co., Ltd. | Method and vaccine comprising copolymer 1 for treatment of psychiatric disorders |
WO2005112972A1 (en) | 2004-05-07 | 2005-12-01 | Peptimmune, Inc. | Methods of treating disease with random copolymers |
ZA200702591B (en) | 2004-09-09 | 2009-03-25 | Teva Pharma | Process for preparation of mixtures of polypeptides using purified hydrobromic acid |
WO2006057003A2 (en) * | 2004-11-29 | 2006-06-01 | Yeda Research And Development Co. Ltd. | Induction of neurogenesis and stem cell therapy in combination with copolymer 1 |
JP2009536157A (ja) | 2006-04-13 | 2009-10-08 | ペプチミューン,インコーポレイテッド | エピトープ透過性の指向された拡張を介した指向性配列ポリマー組成物の設計方法および合成方法 |
US8193147B2 (en) | 2007-09-24 | 2012-06-05 | Hadasit Medical Research Services & Development Ltd. | Use of copolymer 1 for treatment of muscular dystrophy |
AP3467A (en) | 2007-10-16 | 2015-11-30 | Peptimmune Inc | Methods for designing and preparing vaccines comprising directed sequence polymer compositions via the directed expansion of epitopes |
WO2009063459A2 (en) * | 2007-11-13 | 2009-05-22 | Yeda Research And Development Co. Ltd | Synthetic peptide copolymers for treatment of neurodevelopmental disorders |
EA032283B1 (ru) | 2009-08-20 | 2019-05-31 | Йеда Рисерч Энд Дивелопмент Ко. Лтд. | Терапия глатирамером ацетатом с низкой кратностью |
USRE49251E1 (en) | 2010-01-04 | 2022-10-18 | Mapi Pharma Ltd. | Depot systems comprising glatiramer or pharmacologically acceptable salt thereof |
EP2398488B1 (en) * | 2010-01-04 | 2018-11-14 | Mapi Pharma Limited | Depot system comprising glatiramer acetate |
US8377885B2 (en) | 2010-01-04 | 2013-02-19 | Mapi Pharma Ltd. | Depot systems comprising glatiramer or pharmacologically acceptable salt thereof |
US8759302B2 (en) * | 2010-03-16 | 2014-06-24 | Teva Pharmaceutical Industries, Ltd. | Methods of treating a subject afflicted with an autoimmune disease using predictive biomarkers of clinical response to glatiramer acetate therapy in multiple sclerosis |
JP2013541010A (ja) | 2010-10-11 | 2013-11-07 | テバ ファーマシューティカル インダストリーズ リミティド | グラチラマーアセテートに対する臨床的な反応の予測可能なバイオマーカーとしてのサイトカインバイオマーカー |
ES2601892T3 (es) | 2011-04-21 | 2017-02-16 | Mapi Pharma Limited | Pentapolímero aleatorio para el tratamiento de enfermedades autoinmunes |
BR112014008752A2 (pt) | 2011-10-10 | 2017-04-25 | Teva Pharma | polimorfismos de nucleotídeos singulares úteis para predizer a resposta clínica para acetato de glatirâmero |
US20150238582A1 (en) | 2012-09-10 | 2015-08-27 | Yeda Research And Development Co. Ltd. At The Weizmann Institute Of Science | Individualized immunomodulation therapy for neurodegenerative disorders, cns injury and age-related dementia |
BR112019017724A2 (pt) | 2017-03-26 | 2020-03-31 | Mapi Pharma Ltd. | Sistemas depot de glatiramer para tratar formas progressivas de esclerose múltipla |
KR20230128606A (ko) * | 2022-02-28 | 2023-09-05 | 경상국립대학교산학협력단 | 티로신을 유효성분으로 함유하는 알츠하이머병의 예방, 개선 또는 치료용 조성물 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL36670A (en) * | 1971-04-21 | 1974-09-10 | Sela M | Therapeutic basic copolymers of amino acids |
IL113812A (en) * | 1994-05-24 | 2000-06-29 | Yeda Res & Dev | Copolymer-1 pharmaceutical compositions containing it and its use |
CA2320044A1 (en) * | 1998-02-13 | 1999-08-19 | Ruth Maron | Treatment of multiple sclerosis using cop-1 and th2-enhancing cytokines |
-
2001
- 2001-01-22 US US09/765,301 patent/US20020037848A1/en not_active Abandoned
- 2001-01-22 AT AT01906632T patent/ATE314860T1/de active
- 2001-01-22 DK DK01906632T patent/DK1294390T3/da active
- 2001-01-22 JP JP2002501464A patent/JP4328090B2/ja not_active Expired - Fee Related
- 2001-01-22 IL IL15080101A patent/IL150801A0/xx active IP Right Grant
- 2001-01-22 MX MXPA02007109A patent/MXPA02007109A/es active IP Right Grant
- 2001-01-22 WO PCT/US2001/002118 patent/WO2001093893A2/en active IP Right Grant
- 2001-01-22 EP EP01906632A patent/EP1294390B1/en not_active Expired - Lifetime
- 2001-01-22 CA CA2398277A patent/CA2398277C/en not_active Expired - Lifetime
- 2001-01-22 KR KR1020027009275A patent/KR20030007397A/ko not_active Application Discontinuation
- 2001-01-22 DE DE60116467T patent/DE60116467T2/de not_active Expired - Lifetime
- 2001-01-22 NZ NZ520282A patent/NZ520282A/en not_active IP Right Cessation
- 2001-01-22 AU AU34518/01A patent/AU783031B2/en not_active Expired
- 2001-01-22 ES ES01906632T patent/ES2256200T3/es not_active Expired - Lifetime
- 2001-01-22 CN CNB018065910A patent/CN100438906C/zh not_active Expired - Lifetime
-
2002
- 2002-07-18 IL IL150801A patent/IL150801A/en unknown
-
2004
- 2004-03-05 HK HK04101665.8A patent/HK1058892A1/xx not_active IP Right Cessation
-
2006
- 2006-02-16 CY CY20061100219T patent/CY1105263T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
MXPA02007109A (es) | 2002-12-13 |
DE60116467T2 (de) | 2006-11-02 |
JP2004507460A (ja) | 2004-03-11 |
HK1058892A1 (en) | 2004-06-11 |
KR20030007397A (ko) | 2003-01-23 |
DE60116467D1 (de) | 2006-03-30 |
ATE314860T1 (de) | 2006-02-15 |
US20020037848A1 (en) | 2002-03-28 |
WO2001093893A3 (en) | 2002-04-04 |
IL150801A0 (en) | 2003-02-12 |
AU3451801A (en) | 2001-12-17 |
CN100438906C (zh) | 2008-12-03 |
ES2256200T3 (es) | 2006-07-16 |
WO2001093893A2 (en) | 2001-12-13 |
JP4328090B2 (ja) | 2009-09-09 |
NZ520282A (en) | 2004-09-24 |
CA2398277A1 (en) | 2001-12-13 |
DK1294390T3 (da) | 2006-04-03 |
IL150801A (en) | 2007-10-31 |
EP1294390A2 (en) | 2003-03-26 |
EP1294390B1 (en) | 2006-01-04 |
AU783031B2 (en) | 2005-09-15 |
CA2398277C (en) | 2013-09-03 |
CN1462190A (zh) | 2003-12-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1105263T1 (el) | Χρηση συμπολυμepους (copolymer) 1 και συναφων πεπτιδιων και πολυπεπτιδιων και t-λεμφοκυτταρων που εχουν υποβληθει σε αγωγη με αυτα για νευροπροστατευτικη θepαπεια | |
DK1248643T3 (da) | Anvendelse af copolymer 1 og beslægtede peptider og polypeptider og T-celler behandlet dermed til neurobeskyttende terapi | |
ATE186219T1 (de) | Kombination von antihormonale und bindende moleküle zur krebsbehandlung | |
CY1118849T1 (el) | Θεραπεια συνδυασμου για τη θεραπευτικη αγωγη διαταραχων ανεπαρκειας πρωτεϊνης | |
DE69630890D1 (de) | Peptid-immitierende substanzen in der krebstherapie | |
CY1106152T1 (el) | Νεα ανοσογονα αντι-hiv (ανατοξινες), μεθοδοι παρασκευης και εφαρμογη στην προληψη και στην αγωγη του aids | |
DE60023476D1 (de) | Kombination von doctaxel und rhumab her2 zür krebsbehandlung | |
SE8902638L (sv) | Stabiliserade protein- eller peptidkonjugat | |
ATE399553T1 (de) | Pharmazeutische zusammensetzungen mit dextromethorphan und chinidin zur behandlung von neurologischen erkrankungen | |
ATE348632T1 (de) | Prion protein peptide und deren verwendung | |
HRP20010877B1 (en) | Composition for prevention and treatment of amyloidogenic disease | |
GR3035440T3 (en) | Therapeutic uses of bpi protein products for human meningococcemia | |
WO1999060021A3 (en) | Use of activated t cells, nervous system-specific antigens for treating disorders of the nevrous system | |
AR045870A1 (es) | Terapia de combinacion para la infeccion de virus de hepatitis c | |
DE69719754D1 (de) | Therapeutische verwendungen von bpi-protein produkten bei menschen mit durch trauma verursachter blutung | |
ATE419875T1 (de) | Behandlung von sarkom bei menschen mit adenovirus-vektor tnf-alpha | |
ATE485377T1 (de) | Das überleben dopaminerger neuronen fördernde faktoren und deren verwendungen | |
WO1996020950A3 (en) | Compositions and methods for treating rheumatoid arthritis | |
CY1113344T1 (el) | Χρηση της il-21 στον καρκινο και μονοκλωνικα αντισωματα για θεραπευτικη αγωγη στερεων καρκινων | |
ECSP982751A (es) | Uso de aminometil-cromanos sustituidos para el impedimento de la degeneracion neuronal y para el estimulo de la regeneracion neuronal |